



FY 2012 Results 19 September 2012



NEW GROWTH HORIZONS

- Strategic vision & business description
- 2012 financial performance
- Operational review
- Clover's competitive strengths
- New growth horizons
- Outlook & priorities



STRATEGIC VISION

Clover Corporation seeks to:

- Identify, develop and commercialise speciality functional and nutritional ingredients in the growing "nutraceutical" market
- Develop and commercialise leading edge proprietary and patented delivery technology including encapsulation
- Work with innovative and multinational industry partners to leverage core technical and manufacturing strengths to innovate and launch new products and expand in core markets
- While retaining a conservative financial base, deliver growth on earnings and dividends




BUSINESS DESCRIPTION

- Focus on two business units:
 - Clover Corporation focuses on innovation & obtaining the optimal return from proprietary technology
 - Nu-Mega Ingredients commercialises proprietary ingredient delivery and encapsulation technology in targeted value added markets
- Work with customers to identify, design, develop, test & launch new products
- Generate sales directly and through specialist distribution partners
- Maintain strong links with technical & academic agencies including CSIRO
- Employ 33 staff, including 4 PhD's, with offices in Sydney, Melbourne, Brisbane and the UK

OVERVIEW OF NU-MEGA PRODUCTS



Maximize the use of proprietary bioactive delivery technology



CLOVER FY2012 RESULTS year ended 31 July 2012



AUD million	4E Reported 31 July 2012	4E Normalised* 31 July 2012	PCP 1 Aug'10 – 31 Jul '11	4E Reported# 31 July 2011
Revenue	\$38.4	\$38.4	\$32.0	\$35.6
Profit before tax	\$6.4	\$7.4	\$5.2	\$6.1
Depreciation/Amort Interest	(\$0.51) \$0.29	(\$0.51) \$0.29	(\$0.36) \$0.55	(\$0.39) \$0.59
EBITDA	\$6.7	\$7.9	\$5.1	\$5.9
EBIT	\$6.2	\$7.4	\$4.7	\$5.5
Тах	(\$1.99)	(\$1.99)	(\$1.26)	(\$1.53)
NPAT	\$4.4	\$5.6	\$4.0	\$4.6
EPS	2.65 cps	3.38 cps	2.40 cps	2.79 cps
ROE (annualised)	14.5%	18.6%	14.1%	16.4%

* Normalised results are non-statutory measures and represent results from continuing operations. Expenses totalling \$1.22 million in respect of the joint venture, Future Food Ingredients Pty. Limited, have been excluded from the normalised results.
 # Due to change in Financial year includes 13 months from 1 July 2010 to 31 July 2011.

HISTORICAL FINANCIAL PERFORMANCE



AUD million	FY2012	FP2011 (13 months)	FY2010	FY2009	FY2008	FY2007
Shares on issue	165.2 m	165.2 m	165.2 m	165.2 m	165.2 m	165.2 m
Total contributed equity	\$29.9	\$32.9	\$32.9	\$28.3	\$27.0	\$23.7
Cash total	\$9.7	\$7.4	\$12.2	\$9.2	\$10.8	\$11.0
Sales Revenue	\$38.4	\$35.6	\$34.9	\$21.1	\$21.6	\$16.5
Total Revenue	\$38.7	\$36.0	\$35.9	\$22.9	\$22.9	\$17.7
Profit before tax	\$6.4	\$6.1	\$1.6	\$4.5	\$3.0	\$1.3
Profit after tax	\$4.4	\$4.6	(\$0.97)	\$3.1	\$4.1	\$0.6
EPS (cents)	2.60	2.70	(0.59)	1.87	2.5	0.38
Dividend (cps)	1.75	1.50	1.25	1.00	1.00	

CASH FLOW Year ended 31 July 2012



AUD million From Continuing Ops	Reported 31 July 2012
EBITDA	6.7
Working Capital Movement	3.4
Net Interest	0.3
Tax Paid	(2.4)
Cash Flow from Operations	8.0
Financing Activities	(3.8)
Сарех	(1.9)
Free Cash Flow	6.1
Net Increase in Cash Held	9.7



BALANCE SHEET Year ended 31 July 2012

AUD million	Reported 31 July 2012	Reported 31 July 2011	Change %
Cash	9.7	7.4	+31%
Trade Receivables	9.7	10.5	-9%
Inventories	12.3	8.7	+41%
Total Current Assets	31.8	27.1	+17%
PPE/Intangible Assets	5.5	4.1	+34%
Total Assets	38.6	32.3	+20%
Trade Payables	(8.1)	(3.4)	+138%
Total Current Liabilities	(8.4)	(4.0)	+110%
Total Liabilities	(8.7)	(4.3)	+102%
Net Assets	29.9	28.0	+7%

FY2012 HIGHLIGHTS – STRONG UNDERLYING GROWTH



- Strong growth in organic sales revenue (20.7% normalized pcp).
- Focus on infant formula & children applications (2012: 97.4%).
- Continued expansion of sales in Oceania and Asia.
- Increase in proportion of sales from high value encapsulated products (2012: 97%).
- Reduction in costs due to productivity improvements and other efficiencies.
- 5% decrease in underlying NPAT due to costs of \$1.22 million associated with sale of FFI assets. Sales contracts have been exchanged.
- Customer evaluation of new products are underway.
- Innovation program with CSIRO Australian Growth Partnership program underway.
 Due for completion in 2014.
- Novel Food approval by Health Canada for selected encapsulated ingredients.
- Upgrade of the Altona manufacturing facility (\$1.5 million).
- Generating positive free cash flow (2012: \$6.1 million).

CONTINUED FOCUS ON GROWTH MARKETS & VALUE ADDED PRODUCTS



- Sales revenue increased in all regions with the strongest performance in Australia/New Zealand and Asia.
- Focus has been on infant formula & children's food applications.
- The expansion of sales in value added encapsulated ingredient systems.

FY2012 Geographic

Australia/New Zealand	26%
Asia	64%
Europe	6%
Americas	4%


FY2012 Products

Oil	3%
Encapsulated Powders	97%

MULTIPLE GROWTH DRIVERS & DELIVERY



- Maintaining a position at the forefront of technical development for bioactive delivery and encapsulation technology
 - 2 patent applications filed in FY2012
- Working with our customers to develop & provide market relevant proprietary products in a timely manner
- Focus on growing and emerging markets
- Identifying value added applications
- Investigation of specific opportunities for medical foods for preterm infants.




DELIVERY SYSTEMS BASED ON A VARIETY OF NUTRITIONAL BIOACTIVES



• Product portfolio includes refined tuna oil and encapsulated powders containing marine oil, algal oils, other specialty oils and important micronutrients.

• Encapsulation technologies protect important and sensitive nutritional materials and allow their use in many applications. Sales Revenue based on Diversified Bioactives in FY2012




■ Tuna oil encap. ■ Other bioactive encap.

COMPETITIVE STRENGTHS – A CULTURE OF COMMERCIAL INNOVATION




- Clover's core strengths;
 - Growing share in value added markets
 - Proprietary & patented technology
 - Commercial focus with high returns on R&D
 - High quality products & excellent reputation with clients
 - Dedicated and skilled staff
- Long term commercial relationships
- Expanding product portfolio supported by sound science
- Targeted external research program
- Long product life cycle supported by rigorous customer evaluation
- Excellent customer & applications support
- Specialised distribution network
- Low capital model



RESEARCH & DEVELOPMENT EXPENDITURE (EXPENSED IN YEAR OF ACTIVITY)






* FP11 represents 13 months

EXAMPLE OF PRODUCT LIFE CYCLE




Continual product improvement to increase sales



Time

INNOVATION LEADS TO NEW PRODUCTS & REVENUES





SPONSORED RESEARCH **IN 2012**



Heart*Rhythm*

of the Heart Rhythm Society							
Articles and Issues -	Multinedia - 🖉	Article Collections -	For Authors -	Journal Info -	HRS -	Related Sites -	
Search for		in All Fields		∨ Go	Advanced S	learch	
« Previous		Hei Volum e 9, Issue 4	art Rhythm "Pages 483-491, A	pril 2012		Next	

Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion

Saurah Kumur, BSC. (Ner/MBBS. <u>Finna Suthefaud</u>, RN. <u>Joseph B. Mertin, MBBS</u>. (PhD. <u>Gerffry Lee</u>, MBChB. <u>John Henjan</u>, MBBS James Wing, MBBS, PhD. <u>David E. Eccleston</u>, MBBS, Milled, <u>John Workelatos</u>, MBBS, <u>Mannhar L. Gan</u>, PhD. <u>Paul B. Sparis</u>, MBBS, PhD

ublished online 24 November 2011.

Abstract Full Text PDF Images Reitrences Supplemental Materials

Background Persistentatial durillation (AF) is associated with a high risk of recurrence after electrical cardioversion.

Objective

We examined if long-term supplementation with omega-3 polyunsaturated tetty acids in tish oils commenced > 1 month prior to electrical cardioversion and confinued hereafter reduces recurrence of persistent AF.

Methods

This was an open-label, random ized study of 178 patients with persistent AP > 1-month chiration. Participants were assigned to control group (n = 87) or omega-3 group (6 git) fish oil; n = 91) and underwent cardioversion 1 month later. Concurrent and arthythmic use of sofalol or amiodarone was permitted. Fish oil was confined fill return of persistent AF or a maximum of 1 year. Intenfon-to-treat analysis was performed for the primary endpoint defined as the recurrence of persistent AF.

Results

Mean duration of \$5h oil intake was 56 days precardioversion and a total of 242 days in follow-up. Eicosapentaenoic acid and docosabexaenoic acid, the active components of fish oils, were 1.8-fold and 2.1-fold higher, respectively, in the omega-3 group



The effects of 90-day supplementation with the Omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population

Con Stough*#, Luke Downey#, Beata Silber#, Jenny Lloyd#, Christina Kure#, Keith Wesnes**, David Camfield* Multime (NEM) Californative Centre for Neurosquition, Buin Sciences Institute, Swinhurne Unive Technology ¹⁴ United Bacfances Composition, Geolog-on Planes, UK

Bogstool 13 October 2000; expired in errised forte 13 March 2011; accepted 22 March 2011

Aletrat

- construction of the start harmonic and CRU1 () is construct for mercure sites and multi-factograph and factors in the table to the start of the prop neuroining DHA were found to have significantly better right upper visual acuty postnearment in comparison with the plausite group $f(1,22) = 7.651; \rho = 0.611;$ partial $\eta^2 = 0.250$. 2012 Ehuviar Inc. All rights marve

Kowwels: Essential fatty acide: Decondectaensic acid (DBA): Gatantee: Dementia: Nartine: Cognition: Visual Acoity

t. Introduction

Deconductances cald (DHA) is a long chain so-3 poly-montranel farty acid (PUFA) which is commonly found in the olds and commissions more than 30% of the total phon-pholigial composition of planum morefreness in the basis (former-Fullar). (Societized et al. 2002). Epidemiologi-cal and prospective cohort meanth has provided strang-estimate to indicate that a dire high is robated matrice as-3

* Composeling autors at: National Institute of Complementary Moli-ant (NCM). Calaberative Catter for Nationageation, Brain Sciences Institute, Reinburne University of Technology, PO Res 208 Handrein, Melburner Vermin 3222, Australia, Tal; +66 33021+8887; dot: +88 J 2014 5230. E-mail address cromph@resis.eds.os (C. Masghi)

007.45895 - un fron mater & 202 Elsevier Inc. All rights marred doi:10.1016/j.com/initiging.2011.01.019

tion. In an extensive review of DHA clinical trials in dementia, Canuare and colleagues (2004) concluded that there is currently greater evidence for DHA playing a pre-ventive rather than curative role in dementia. Intervention ventre rather than control one in dementa, thereman tradies that have investigated the cognitive benefits associ-ated with DHA supplementation in healthy elderly individ-uals without evidence of detectria have also yielded mixed results, with some reporting modest cognitive improve-ments (Fourieri et al., 2005; Johnson et al., 2008; Yarko-Maaro et al., 2010), while a large study by Van De Rest et

in linked to a lowered risk of coparitive decline and Alzhei-mer's disease (AD) (Brydeon et al., 2007; Morris et al., 2005; Van Gelder et al., 2007). However, chincal evidence for the efficacy of D01A in antifumating cognitive decline has not been without conten-

ACENC

CONCLUSIONS: The importe apportantion of Seal accords with actual local



141

......

eLittiers

Hama About Current larue AAP Policy eAphives Supplements Collections eLatters Early Releases Contact Us

Article

Impaired Fetal Growth and Arterial Wall Thickening: A Randomized Trial of Omega-3 Supplementation

Michael 8. Skilton, Ph0⁸, Julian C. Ayer, MISS, Ph0⁹, Jason A. Harmer, 85c⁸, Karen Webb, MPH, PhD⁴, Stephen R. Leeder, ND, Ph0^d, Guy B. Marks, MBES, Ph0⁴, and David 5. Celermajer, MBBS, PhD

· Author Affiliations

ABSTRACT

OBJECTIVES: Inpaired fetal growth is an independent cardiovascular risk factor and it associated with americal wall shickening in children. No preventive strategy has been identified. We sought to determine whether distany onega-3 fatty acid supplementation during early childhood prevents the appociation between impaired fetal growth and carotid arterial wall thickening

METHODS: The Childhood Asthma Prevention Study reas a randomized, controlled single-blind trial in EIS children born at term, recruited armentally from naternity hospitals in Sydney Participants were nerdonized to either a 100 mg-daily faih oil tupplement and canola-based margarities and cooling oil (onega-1 group), or a 500 mg-daily samflower oil supplement and onega-5 faity acid-rich reargantees and cooling oil kontrol group), from the start of bottle-feeding or 6 months of age until 5 years of age. Calottid intera-media thickness BMD, a noninvasive mossure of subclinical atherosclerosis, was the primary endpoint of a cardiovascula mintudy (CardoCAPS) at uge 8 years. We scanned the association of Hall growth with carotid IMT in children with birth weight <00th percentile Isrnega-3 group [n = 187] control group (n = 1763).

RESULTS: In the control group, fetal growth was inversely associated with carotid MIT, but this was prevented in the snegar-1 group Gifference between groups of 0.041 km 35% confidence interval 0.006, 0.0751 per kg birth weight, adjusted for gestational age and gender. $P_{\rm bytemperator} = 0.2$



NEW GROWTH HORIZONS



• Continued focus on the infant formula and children's food market.

- Specialist delivery systems.
- Targeted multiple bioactive delivery systems.
- Improved bioactive protection.
- Provision of improved value.
- Develop medical food opportunities
 - products for improved cognitive & respiratory development in preterm infants.
 - Product development supported by a major clinical trial underway
- Exploring new ways to commercialize Clover intellectual property including licensing.
 - The outcomes for the innovation program may have applicability beyond Clover's commercial focus.
- Assessing new bioactives.
- Developing new markets/applications.



FY2013 OUTLOOK & PRIORITIES

- Outlook is promising for FY2013 following the good performance in FY2012.
- Continued organic growth with emphasis on Oceania, Asia and the Americas.
- Initial sales from products provided for customer evaluation in 2011.
- Advance the innovation program for specialty infant formula ingredients and medical food applications.
- Competitive market will continue to see pressure on product margins.
- Continue to improve efficiencies and reduce costs.



THANK YOU Questions?



DISCLAIMER

The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions.

This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law.

Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor. Certain statements made in this presentation are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Clover Corporation's current expectations, estimates and projections about the industry in which Clover Corporation operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and similar expressions are intended to identify forward-looking statements.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Clover Corporation, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Clover Corporation cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Clover Corporation only as of the date of this presentation. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Clover Corporation will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.